In a big win for its surgical business, Durham-based Bioventus says all of its surgical orthobiologics products are now available through Premier Inc., a large group purchasing organization consisting of 3,750 U.S. hospitals and more than 130,000 other healthcare providers.
The company’s Osteoamp, an allograft fusion solution, has been available through Premier since 2012, Bioventus said in a news release. Additional products now available as of June 1 include Signafuse, a bioactive bone graft substitute; Exponent, a demineralized bone matrix; Purebone, demineralized cancellous bone and cancellous chips; Interface, a bioactive bone graft; Osteomatrix, a biphasic mineral/collagen bone graft; Osteoplus, a biphasic mineral bone graft; Cellxtract, an autologous cell and marrow extraction device; and Extractor, an autologous cell and marrow extraction device.
“The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients across a broad range of clinical situations, procedures, and costs,” said Henry Tung, M.D., senior vice president of Bioventus and president of Bioventus Surgical. “We expect the Premier alliance of hospitals and healthcare providers to benefit greatly from our clinically supported and cost-effective orthobiologic solutions.”
In addition to its Surgical portfolio, Bioventus has an Active Healing Therapies business, anchored by Exogen, a low-intensity pulsed ultrasound that stimulates bone healing. EXOGEN has been used to treat more than 1 million patients worldwide and is the leading bone-healing system in the market, the company said.
Bioventus was formed in 2012 when Smith & Nephew, a global medical technology business, spun out its biologics division in Durham in partnership with Essex Woodlands, a healthcare growth equity firm, and other investors. The company has about 660 employees worldwide and annual revenues of about $250 million, according to its website.
(C) N.C. Biotechnology Center
